[Review of 32 gastro-intestinal stromal tumours with CD117 antigen].

Revision de 32 tumeurs mesenchymateuses gastro-intestinales avec le CD117.

Publisher: Societe Tunisienne Des Sciences Medicales Country of Publication: Tunisia NLM ID: 0413766 Publication Model: Print Cited Medium: Print ISSN: 0041-4131 (Print) Linking ISSN: 00414131 NLM ISO Abbreviation: Tunis Med Subsets: MEDLINE

Original Publication: Tunis : Societe Tunisienne Des Sciences Medicales

Biomarkers, Tumor/*metabolism ; Duodenal Neoplasms/*metabolism ; Gastrointestinal Stromal Tumors/*metabolism ; Ileal Neoplasms/*metabolism ; Jejunal Neoplasms/*metabolism ; Proto-Oncogene Proteins c-kit/*metabolism ; Stomach Neoplasms/*metabolism; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Benzamides ; Duodenal Neoplasms/diagnosis ; Duodenal Neoplasms/drug therapy ; Duodenal Neoplasms/surgery ; Female ; Gastrointestinal Stromal Tumors/diagnosis ; Gastrointestinal Stromal Tumors/drug therapy ; Gastrointestinal Stromal Tumors/surgery ; Humans ; Ileal Neoplasms/diagnosis ; Ileal Neoplasms/drug therapy ; Ileal Neoplasms/surgery ; Imatinib Mesylate ; Jejunal Neoplasms/diagnosis ; Jejunal Neoplasms/drug therapy ; Jejunal Neoplasms/surgery ; Male ; Middle Aged ; Piperazines/therapeutic use ; Pyrimidines/therapeutic use ; Retrospective Studies ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/surgery ; Treatment Outcome

Aim: The aim of this study is to review clinical data, histological and immunohistochemical findings and prognosis of stromal gastrointestinal tumors.
Methods: A retrospective Study of 32 cases of stromal gastrointestinal tumors diagnosed in the Department of Pathology of Mongi Slim Hospital of Tunis from 1991 to 2004.
Results: The average age of the patients was of 54.4 years, equal for sex. Tumors were essentially gastric (50%) and of the small intestine (37.5%). All the patients had surgical treatment. Gastro-intestinal Stromal Tumors or GIST represent the most frequent stromal tumor with 56.2% of cases.
Conclusion: After immunohistochimestry study, using CD117 antigen, this revision allows better management of GIST. Glivec is the standard treatment of advanced GIST.

0 (Antineoplastic Agents)
0 (Benzamides)
0 (Biomarkers, Tumor)
0 (Piperazines)
0 (Pyrimidines)
8A1O1M485B (Imatinib Mesylate)
EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)

Date Created: 20090616 Date Completed: 20090731 Latest Revision: 20151119

20250114

19522447